Bildkälla: Stockfoto

Initiator Pharma: Positive Topline Data for IPTN2021 - Redeye

Following the completion of the first clinical Proof-of-Principle (PoP) study in the IPTN2021 program, Initiator Pharma today announced that an analysis of the first data read-out has been obtained. The candidate demonstrated a statistically significant pain-reducing effect with limited side effects.

Following the completion of the first clinical Proof-of-Principle (PoP) study in the IPTN2021 program, Initiator Pharma today announced that an analysis of the first data read-out has been obtained. The candidate demonstrated a statistically significant pain-reducing effect with limited side effects.
Börsvärldens nyhetsbrev
ANNONSER